Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 5, 2009, Pages

  Chen, Junqin ^a   Hyunjoo, Cha Molstad ^a   Szabo, Anna ^a   Shalev, Anath ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Cardiomyocyte apoptosis; Diabetic cardiomyopathy; Verapamil

Indexed keywords

CASPASE 3; THIOREDOXIN INTERACTING PROTEIN; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; HEART MUSCLE CELL; MALE; MOUSE; NONHUMAN; NONSENSE MUTATION; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

ANIMALS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CARRIER PROTEINS; CASPASE 3; CELL LINE; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCOSE; IMMUNOBLOTTING; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MYOCYTES, CARDIAC; RATS; THIOREDOXINS; VERAPAMIL;

EID: 66149156413     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90944.2008     Document Type: Article

References (35)

1. Afzal N, Ganguly PK, Dhalla KS, Pierce GN, Singal PK, Dhalla NS. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37: 936-942, 1988. (Pubitemid 19043725)
2. Bodnar JS, Chatterjee A, Castellani LW, Ross DA, Ohmen J, Cavalcoli J, Wu C, Dains KM, Catanese J, Chu M, Sheth SS, Charugundla K, Demant P, West DB, de Jong P, Lusis AJ. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet 30: 110-116, 2002.
3. Brickson S, Fitzsimons DP, Pereira L, Hacker T, Valdivia H, Moss RL. In vivo left ventricular functional capacity is compromised in cMyBP-C null mice. Am J Physiol Heart Circ Physiol 292: H1747-H1754, 2007. (Pubitemid 46572397)
4. Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 346: 1067-1074, 2006. (Pubitemid 43913716)
5. Chen J, Hui ST, Couto FM, Mungrue IN, Davis DB, Attie AD, Lusis AJ, Davis RA, Shalev A. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta cell mass and protects against diabetes. FASEB J 22: 3581-3594, 2008.
6. Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta cell apoptosis. Diabetes 57: 938-944, 2008.
7. Cohn RD, Durbeej M, Moore SA, Coral-Vazquez R, Prouty S, Campbell KP. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 107: R1-R7, 2001. (Pubitemid 32096840)
8. Dentin R, Hedrick S, Xie J, Yates J 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science 319: 1402-1405, 2008.
9. Dyntar D, Sergeev P, Klisic J, Ambuhl P, Schaub MC, Donath MY. High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation. J Clin Endocrinol Metab 91: 1961-1967, 2006.
10. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T, Salio M, Savino C, Melucci S, Santangelo F, Scanziani E, Masson S, Ghezzi P, Latini R. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37: 959-968, 2004. (Pubitemid 39446821)
11. Hui TY, Sheth SS, Diffley JM, Potter DW, Lusis AJ, Attie AD, Davis RA. Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem 279: 24387-24393, 2004.
12. Jansson D, Ng AC, Fu A, Depatie C, Al Azzabi M, Screaton RA. Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2. Proc Natl Acad Sci USA 105: 10161-10166, 2008.
13. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, Choi I. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164: 6287-6295, 2000. (Pubitemid 30408809)
14. Karar J, Dolt KS, Mishra MK, Arif E, Javed S, Pasha MA. Expression and functional activity of pro-oxidants and antioxidants in murine heart exposed to acute hypobaric hypoxia. FEBS Lett 581: 4577-4582, 2007. (Pubitemid 47418780)
15. Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 66: 1449-1452, 1990.
16. 2+-operated transcriptional networks: molecular mechanisms and in vivo models. Physiol Rev 88: 421-449, 2008.
17. Messerli FH. What, if anything, is controversial about calcium antagonists? Am J Hypertens 9: 177S-181S, 1996.
18. Minn AH, Hafele C, Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146: 2397-2405, 2005. (Pubitemid 40577527)
19. Minn AH, Pise-Masison CA, Radonovich M, Brady JN, Wang P, Kendziorski C, Shalev A. Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochem Biophys Res Commun 336: 770-778, 2005. (Pubitemid 41338335)
20. Nishiyama A, Masutani H, Nakamura H, Nishinaka Y, Yodoi J. Redox regulation by thioredoxin and thioredoxin-binding proteins. IUBMB Life 52: 29-33, 2001. (Pubitemid 33769666)
21. O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 82: 881-887, 1998.
22. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT. The interaction of thioredoxin with Txnip: evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 281: 21884-21891, 2006. (Pubitemid 44181892)
23. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290: 2805-2816, 2003. (Pubitemid 37509488)
24. Schulze PC, Liu H, Choe E, Yoshioka J, Shalev A, Bloch KD, Lee RT. Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity. Arterioscler Thromb Vasc Biol 26: 2666-2672, 2006.
25. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279: 30369-30374, 2004. (Pubitemid 38937964)
26. Shalev A, Pise-Masison CA, Radonovich M, Hoffmann SC, Hirshberg B, Brady JN, Harlan DM. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 143: 3695-3698, 2002.
27. Sheth SS, Castellani LW, Chari S, Wagg C, Thipphavong CK, Bodnar JS, Tontonoz P, Attie AD, Lopaschuk GD, Lusis AJ. Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition. J Lipid Res 46: 123-134, 2005. (Pubitemid 40066678)
28. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113: 544-554, 2006. (Pubitemid 43754355)
29. Wang Y, De Keulenaer GW, Lee RT. Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 277: 26496-26500, 2002.
30. World CJ, Yamawaki H, Berk BC. Thioredoxin in the cardiovascular system. J Mol Med 84: 997-1003, 2006.
31. Xiang G, Seki T, Schuster MD, Witkowski P, Boyle AJ, See F, Martens TP, Kocher A, Sondermeijer H, Krum H, Itescu S. Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem 280: 39394-39402, 2005. (Pubitemid 41713897)
32. Yamanaka H, Maehira F, Oshiro M, Asato T, Yanagawa Y, Takei H, Nakashima Y. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 271: 796-800, 2000. (Pubitemid 30444707)
33. Yamawaki H, Pan S, Lee RT, Berk BC. Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest 115: 733-738, 2005. (Pubitemid 40322249)
34. Yoshioka J, Imahashi K, Gabel SA, Chutkow WA, Burds AA, Gannon J, Schulze PC, MacGillivray C, London RE, Murphy E, Lee RT. Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101: 1328-1338, 2007. (Pubitemid 350294650)
35. Zhang M, Kho AL, Anilkumar N, Chibber R, Pagano PJ, Shah AM, Cave AC. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 113: 1235-1243, 2006. (Pubitemid 43754249)